These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 27249556)

  • 21. Clinical impact of nonsustained ventricular tachycardia recorded by the implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy.
    Francia P; Santini D; Musumeci B; Semprini L; Adduci C; Pagannone E; Proietti G; Volpe M; Autore C
    J Cardiovasc Electrophysiol; 2014 Nov; 25(11):1180-7. PubMed ID: 25066044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ventricular arrhythmias and left ventricular hypertrophy in hypertrophic cardiomyopathy.
    Piva e Mattos B; Torres MA; Freitas VC; Scolari FL; Loreto MS
    Arq Bras Cardiol; 2013 May; 100(5):452-9. PubMed ID: 23579622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Burden of premature ventricular contractions beyond nonsustained ventricular tachycardia is related to the myocardial extracellular space expansion in patients with hypertrophic-cardiomyopathy.
    Chung H; Park CH; Kim Y; Kim JY; Min PK; Yoon YW; Lee KA; Lee BK; Hong BK; Kim TH; Rim SJ; Kwon HM; Choi EY
    Clin Cardiol; 2020 Nov; 43(11):1317-1325. PubMed ID: 32815161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversed Septal Curvature Is Associated With Nonsustained Ventricular Tachycardia in Hypertrophic Cardiomyopathy.
    He Y; Zhou J
    Am J Cardiol; 2024 Jan; 210():195-200. PubMed ID: 37884111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The relationship between QT dispersion and risk factors of sudden death in hypertrophic cardiomyopathy].
    Göktekin O; Ritsushi K; Matsumoto K; Hiroshi M
    Anadolu Kardiyol Derg; 2002 Sep; 2(3):226-30. PubMed ID: 12223331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonsustained ventricular tachycardia as a predictor for sudden death in patients with idiopathic dilated cardiomyopathy. The role of amiodarone treatment.
    Castelli G; Ciaccheri M; Cecchi F; Troiani V; Nannini M; Marconi P; Olivotto J; Montereggi A; Dolara A
    G Ital Cardiol; 1999 May; 29(5):514-23. PubMed ID: 10367218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of the corrected QT before the onset of nonsustained ventricular tachycardia in patients with hypertrophic cardiomyopathy.
    Baranowski R; Chojnowska L; Michalak E; Orłowska-Baranowska E
    Pacing Clin Electrophysiol; 2003 Jan; 26(1P2):387-9. PubMed ID: 12687851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance.
    Adabag AS; Maron BJ; Appelbaum E; Harrigan CJ; Buros JL; Gibson CM; Lesser JR; Hanna CA; Udelson JE; Manning WJ; Maron MS
    J Am Coll Cardiol; 2008 Apr; 51(14):1369-74. PubMed ID: 18387438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Usefulness of 14-Day Holter for Detection of Nonsustained Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy.
    Weissler-Snir A; Chan RH; Adler A; Care M; Chauhan V; Gollob MH; Ziv-Baran T; Fourey D; Hindieh W; Rakowski H; Spears DA
    Am J Cardiol; 2016 Oct; 118(8):1258-1263. PubMed ID: 27567133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of Myocardial Disarray in Patients With Hypertrophic Cardiomyopathy and Ventricular Arrhythmias.
    Ariga R; Tunnicliffe EM; Manohar SG; Mahmod M; Raman B; Piechnik SK; Francis JM; Robson MD; Neubauer S; Watkins H
    J Am Coll Cardiol; 2019 May; 73(20):2493-2502. PubMed ID: 31118142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical significance of T-wave alternans in hypertrophic cardiomyopathy.
    Kuroda N; Ohnishi Y; Yoshida A; Kimura A; Yokoyama M
    Circ J; 2002 May; 66(5):457-62. PubMed ID: 12030340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy.
    Gawor M; Śpiewak M; Janas J; Kożuch K; Wróbel A; Mazurkiewicz Ł; Baranowski R; Marczak M; Grzybowski J
    Kardiol Pol; 2017; 75(10):997-1004. PubMed ID: 28612913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac troponin I is associated with non-sustained ventricular tachycardia in patients with hypertrophic obstructive cardiomyopathy.
    Zhou Y; Yu M; Yuan J; Liu S; Hu F; Yang Z; Cui J; Qiao S
    Heart Vessels; 2020 Jun; 35(6):876-885. PubMed ID: 31907598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The significance of paced electrogram fractionation in hypertrophic cardiomyopathy. A prospective study.
    Saumarez RC; Slade AK; Grace AA; Sadoul N; Camm AJ; McKenna WJ
    Circulation; 1995 Jun; 91(11):2762-8. PubMed ID: 7758182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonsustained Ventricular Tachycardia Is Independently Associated With Sustained Ventricular Arrhythmias in Nonischemic Dilated Cardiomyopathy.
    Piers SR; Androulakis AF; Yim KS; van Rein N; Venlet J; Kapel GF; Siebelink HM; Lamb HJ; Cannegieter SC; Man SC; Zeppenfeld K
    Circ Arrhythm Electrophysiol; 2022 Feb; 15(2):e009979. PubMed ID: 35089806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. QT-interval abnormalities in hypertrophic cardiomyopathy.
    Dritsas A; Sbarouni E; Gilligan D; Nihoyannopoulos P; Oakley CM
    Clin Cardiol; 1992 Oct; 15(10):739-42. PubMed ID: 1395184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extended Ambulatory ECG Monitoring Enhances Identification of Higher-Risk Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy.
    Rowin EJ; Das G; Madias C; Hsu M; Crosson L; Turakhia MP; Maron BJ; Maron MS
    Heart Rhythm; 2024 Sep; ():. PubMed ID: 39307380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of intra-left ventricular electromechanical asynchrony in patients with mild hypertrophic cardiomyopathy compared with power athletes.
    D'Andrea A; Caso P; Cuomo S; Salerno G; Scarafile R; Mita C; De Corato G; Sarubbi B; Scherillo M; Calabrò R
    Br J Sports Med; 2006 Mar; 40(3):244-50; discussion 244-50. PubMed ID: 16505082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. QRS Fragmentation and QTc Duration Relate to Malignant Ventricular Tachyarrhythmias and Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy.
    Debonnaire P; Katsanos S; Joyce E; VAN DEN Brink OV; Atsma DE; Schalij MJ; Bax JJ; Delgado V; Marsan NA
    J Cardiovasc Electrophysiol; 2015 May; 26(5):547-55. PubMed ID: 25648421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of nonsustained ventricular tachycardia and programmed ventricular stimulation for risk stratification in patients with idiopathic dilated cardiomyopathy.
    Becker R; Haass M; Ick D; Krueger C; Bauer A; Senges-Becker JC; Voss F; Hilbel T; Niroomand F; Katus HA; Schoels W
    Basic Res Cardiol; 2003 Jul; 98(4):259-66. PubMed ID: 12835955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.